OCALA, FL / ACCESSWIRE / September 10, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) today announced that the company will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020.
Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to present on Monday, September 14 at 5:00 p.m., Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Contacts:
Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com
AIM ImmunoTech Inc
Phone: 800-778-4042
Email: IR@aimimmuno.com
SOURCE: AIM ImmunoTech Inc.
View source version on accesswire.com:
https://www.accesswire.com/605463/AIM-ImmunoTech-to-Present-at-the-HC-Wainwright-22nd-Annual-Global-Investment-Conference-on-September-14th
Real-World testing nanotechnology to provide insights for manufacturing process with DunmoreOakville, Ontario--(Newsfile Corp. - July…
CordenPharma is making a record investment of ~€900m over the next 3 years in expanding…
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (Nasdaq: MASI), a global leader in noninvasive…
Henry Charlton and Claire Poulard to join the Board of Directors Funding will Accelerate US…
NEW YORK, July 15, 2024 /PRNewswire/ -- The global trenbolone enanthate market size is estimated to grow by…
NEW YORK, July 15, 2024 /PRNewswire/ -- The global mindfulness meditation application market size is…